Silo Pharma (NASDAQ:SILO) Posts Quarterly Earnings Results

Silo Pharma (NASDAQ:SILO) released its quarterly earnings data on Friday. The company reported $0.03 earnings per share (EPS) for the quarter, FiscalAI reports. The business had revenue of $0.02 million during the quarter. Silo Pharma had a negative return on equity of 107.03% and a negative net margin of 7,050.00%.

Silo Pharma Price Performance

NASDAQ SILO opened at $0.34 on Friday. Silo Pharma has a 12 month low of $0.22 and a 12 month high of $1.30. The firm has a market capitalization of $4.53 million, a PE ratio of -0.36 and a beta of 0.39. The company’s 50 day simple moving average is $0.34 and its 200 day simple moving average is $0.45.

Institutional Trading of Silo Pharma

Several institutional investors have recently modified their holdings of SILO. AdvisorShares Investments LLC grew its holdings in Silo Pharma by 98.0% during the third quarter. AdvisorShares Investments LLC now owns 364,878 shares of the company’s stock worth $252,000 after acquiring an additional 180,642 shares during the period. Virtu Financial LLC acquired a new stake in Silo Pharma in the 3rd quarter valued at about $74,000. Anson Funds Management LP bought a new position in shares of Silo Pharma during the 3rd quarter valued at about $657,000. Geode Capital Management LLC boosted its position in shares of Silo Pharma by 134.6% during the 4th quarter. Geode Capital Management LLC now owns 92,905 shares of the company’s stock valued at $32,000 after purchasing an additional 53,309 shares in the last quarter. Finally, DRW Securities LLC acquired a new position in shares of Silo Pharma in the 4th quarter worth approximately $113,000. Institutional investors and hedge funds own 5.58% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Silo Pharma in a report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

About Silo Pharma

Silo Pharma, Inc (NASDAQ:SILO) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel psychedelic and related synthetic therapies. Headquartered in New York City, the company applies proprietary chemistry and targeted drug delivery approaches to advance candidates that address critical unmet needs across oncology, neurology and mental health.

The company’s preclinical and early-stage clinical pipeline comprises several programs that explore serotonin receptor modulators, synthetic analogs of classic psychoactive compounds and neuroprotective agents.